Breast cancer has variability from the different cell types with different patterns of gene expression in breast cancer, but a new study found that that variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients. These findings were presented at the 5th IMPAKT Breast Cancer Conference.
No significant difference in morbidity, cancer control for men treated post-prostatectomy using Intensity-modulated radiotherapy (IMRT) over conformal radiotherapy (CRT).
Initial results confirm more positive screening results, diagnostic procedures, cancer ID'd with CT versus standard chest X-rays.
Among women with estrogen-receptor positive breast cancer, late recurrence was best predicted by the clinical treatment score. Significant prognostic value was added by the PAM50 risk of recurrence score and by the Breast Cancer Index score, according to a study comparing five scores that was presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.
Women with breast cancer who had the strongest social relationships were likeliest to report fewer symptoms and the best overall quality of life.
Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent of the molecular pathways that could be expected to be involved.
A new class of drugs targeting the genetic material of skin cancer has been successfully tested in humans for the first time. This opens the way to new treatments for a range of conditions from skin cancers to eye diseases.
The FDA is proposing that indoor tanning beds and booths carry labels that warn minors not to use these products.
Men who reported sleep problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to recently published data.
For older men with nonmetastatic prostate cancer, comorbidities increase risk of other-cause death mortality.
Orally administered rigosertib was found to be well-tolerated in patients with advanced solid tumors in a phase 1 trial. Rigosertib is a dual kinase inhibitor, and this trial is the first to study its orally administered form in solid tumors.
Later-stage breast cancers tend to have more mutations and are more heterogeneous than early-stage cancers. Now, new findings demonstrate that heterogeneity is prevalent even within legions of DCIS.
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors.
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy. A new study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|